SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients

Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its lead drug candidate

Benzinga · -

Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its lead drug candidate repotrectinib in pediatric patients with ALK-, NTRK- and ROS1-positive solid tumors.